$131.54
3.13% yesterday
Nasdaq, Oct 31, 09:03 pm CET
ISIN
US89377M1099
Symbol
TMDX

TransMedics Group, Inc. Stock price

$131.54
+19.34 17.24% 1M
+39.53 42.96% 6M
+69.19 110.97% YTD
+49.57 60.47% 1Y
+83.32 172.79% 3Y
+119.63 1,004.45% 5Y
+115.54 722.13% 10Y
+115.54 722.13% 20Y
Nasdaq, Closing price Fri, Oct 31 2025
-4.25 3.13%

Key metrics

Basic
Market capitalization
$4.6b
Enterprise Value
$4.7b
Net debt
$110.3m
Cash
$400.6m
Shares outstanding
34.0m
Valuation (TTM | estimate)
P/E
77.2 | 56.2
P/S
8.7 | 7.6
EV/Sales
8.9 | 7.7
EV/FCF
273.2
P/B
14.6
Financial Health
Equity Ratio
28.4%
Return on Equity
15.5%
ROCE
9.2%
ROIC
15.5%
Debt/Equity
1.6
Financials (TTM | estimate)
Revenue
$531.3m | $612.9m
EBITDA
$76.9m | $139.2m
EBIT
$76.6m | $96.5m
Net Income
$71.7m | $82.2m
Free Cash Flow
$17.4m
Growth (TTM | estimate)
Revenue
48.1% | 38.8%
EBITDA
12,703.3% | 269.3%
EBIT
9,577.4% | 157.3%
Net Income
2,288.7% | 131.9%
Free Cash Flow
109.0%
Margin (TTM | estimate)
Gross
59.8%
EBITDA
14.5% | 22.7%
EBIT
14.4%
Net
13.5% | 13.4%
Free Cash Flow
3.3%
More
EPS
$1.8
FCF per Share
$0.5
Short interest
40.2%
Employees
728
Rev per Employee
$610.0k
Show more

Is TransMedics Group, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.

TransMedics Group, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a TransMedics Group, Inc. forecast:

13x Buy
72%
5x Hold
28%

Analyst Opinions

18 Analysts have issued a TransMedics Group, Inc. forecast:

Buy
72%
Hold
28%

Financial data from TransMedics Group, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
531 531
48% 48%
100%
- Direct Costs 214 214
52% 52%
40%
318 318
46% 46%
60%
- Selling and Administrative Expenses 177 177
25% 25%
33%
- Research and Development Expense 64 64
14% 14%
12%
77 77
12,703% 12,703%
14%
- Depreciation and Amortization 0.30 0.30
50% 50%
0%
EBIT (Operating Income) EBIT 77 77
9,577% 9,577%
14%
Net Profit 72 72
2,289% 2,289%
13%

In millions USD.

Don't miss a Thing! We will send you all news about TransMedics Group, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

TransMedics Group, Inc. Stock News

Neutral
PRNewsWire
about 7 hours ago
ANDOVER, Mass. , Oct. 31, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on October 27, 2025, TransMedics granted non-qualified stock options to purchase an aggregate of 27,582 shares of its common stock and an ...
Positive
Seeking Alpha
about 11 hours ago
TransMedics delivered solid year-over-year growth in Q3, despite seasonal weakness and concerns over U.S. liver market saturation. The next-gen heart and lung trials, along with an increased focus on international expansion, will be supportive of growth going forward. While TransMedics faces margin headwinds in the short term, profitability continues to improve and will be supportive of the com...
Positive
Seeking Alpha
one day ago
TransMedics shares dropped after Q3 results beat consensus but missed high investor expectations, creating a favorable entry point. Q3 is seasonally weak for TMDX, but the current selloff makes valuation attractive and expectations more reasonable. Industry data signals a strong Q4 ahead, supporting the case for near-term upside in TMDX.
More TransMedics Group, Inc. News

Company Profile

TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.

Head office United States
CEO Waleed Hassanein
Employees 728
Founded 1998
Website www.transmedics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today